Japanese encephalitis (JE) remains the leading cause of viral encephalitis in the Asia-Pacific region, and the live vaccine SA14-14-2 is currently recommended by WHO and widely used in Asian countries with a good safety and efficacy profile. In this study, we demonstrated that SA14-14-2 failed to produce NS1', the larger NS1-related protein, compared with its parental strain SA14 in various cells. Sequence analysis and secondary structure prediction identified a single silent mutation G66A in the NS2A-coding region of SA14-14-2 destabilized the conserved pseudoknot structure, which was associated with a "1 ribosomal frame shift event. Using reverse genetic technology and animal study, we provided solid evidence that this single silent mutation G66A in the NS2A gene abolished the production of NS1' in vitro and reduced neurovirulence and neuroinvasiveness in mice. These findings provide critical information in understanding the molecular mechanism of JE vaccine attenuation and is critical for JE vaccine quality control.
The mosquito-borne Japanese encephalitis virus (JEV) is a member of the family Flaviviridae, genus Flavivirus. Other related pathogenic flaviviruses include West Nile virus (WNV), dengue virus, yellow fever virus and tick-borne encephalitis virus. Japanese encephalitis (JE) caused by JEV remains the most common endemic viral encephalitis in the world especially in the Asia-Pacific region (van den Hurk et al., 2009) . Approximately, 50 000 cases of disease with 10 000 deaths are reported annually, and nearly half of the survivors have neurological and psychiatric sequelae (Erlanger et al., 2009; Solomon, 2003) . Recently, JE has been well recognized as an emerging infectious disease because it is expanding its geographical distribution into new areas of Asia and Australia (Mackenzie et al., 2004) . JEV contains one serotype but five genotypes, and the continuing genotype replacement in Asia arouses significant public health concern Pan et al., 2011) .
There is no specific treatment for JE and vaccine immunization is the effective measure for disease control. Currently, two killed and one live JE vaccine have been approved for human use (Halstead & Thomas, 2010; Solomon, 2004) . However, many countries in endemic areas cannot implement large-scale immunization due to the high cost of killed vaccines (Halstead & Thomas, 2011; Mackenzie et al., 2004; Solomon, 2003) . The liveattenuated JE vaccine (SA14-14-2) was first licensed for vaccination in 1989 in China, and has now been licensed in Nepal, India, Thailand, Sri Lanka, Cambodia, South Korea and other Asian countries (Yu, 2010) . The vaccine has been used in more than 300 million children and it has exhibited an excellent safety profile and an ideal efficacy (Bista et al., 2001; Gatchalian et al., 2008; Hennessy et al., 1996; Kumar et al., 2009; Tandan et al., 2007 by serial passage and plaque purification from strain SA14 (Yu, 2010) . Compared with its parental strain SA14-14-2 is highly attenuated in mice, hamsters and monkeys.
The genome of JEV is a positive-sense ssRNA of about 11 kb, which encodes three structural proteins (C, prM and E) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5). NS1 is a multifunctional protein involved in virus replication and assembly (Khromykh et al., 1999; Lindenbach & Rice, 1997; Winkelmann et al., 2011) , as well as the regulation of host immune response (Avirutnan et al., 2007 (Avirutnan et al., , 2010 Chung et al., 2006 Chung et al., , 2007 Lin et al., 1998; Youn et al., 2010) . A larger NS1-related protein, NS1', has been detected in JEVinfected cells (Blitvich et al., 1999; Chen et al., 1996; Mason, 1989) . Bioinformatic analysis revealed the presence of conserved canonical frameshift-stimulating motifs, a slippery heptanucleotide and a 39-adjacent potential pseudoknot near the beginning of the NS2A gene (Firth & Atkins, 2009) , and the NS1' of JEV serogroup flavivirus was thought to be a product of a 21 ribosomal frame shift event (Firth & Atkins, 2009) . Recently, Melian et al. (2010) have experimentally demonstrated the critical role of the pseudoknot structure-dependent frameshifting in NS1' production and virulence of WNV.
In this study, to examine the expression profile of NS1 and NS1' in JEV-infected cells, mammalian BHK-21 cells were infected with SA14 and SA14-14-2 at an m.o.i. of 0.1, respectively. At 48 h post-infection (p.i.), cell lysates were subjected to Western blotting assay using the JEV NS1-specific mAb 4M7 (Wang et al., 2009) . As shown in Fig.  1(a) , both NS1 and the larger NS1' were detected in SA14-infected cells, whereas only NS1 was detected in the SA14-14-2-infected cells. Similar results were also observed in JEV-infected mosquito C6/36 cells (Fig. 1a) . Then, to dissect the deficiency in NS1' production in SA14-14-2-infected cells, we compared the nucleotide sequences of SA14-14-2 with its parental strain SA14 and other isolates of the JEV serogroup. Sequence alignment of the NS1-NS2A genes showed that a unique 'A' at nt 66 was identified in the NS2A-coding sequence of SA14-14-2, whereas all the other JEV serogroup isolates were 'G' at the same position (Fig. 1b) . Secondary structure analysis of the corresponding regions using the pknotsRG software (Reeder et al., 2007) predicted the slippery heptanucleotide (CCCUUUU) followed by a pseudoknot structure, forming a classical stimulatory motif for 21 ribosomal frameshifting (Firth & Atkins, 2009; Firth et al., 2010) . The single nucleotide difference (G66A) in the corresponding region of SA14-14-2 significantly shortened the length of stem 1 and destabilized the pseudoknot structure according to free energy ( Fig. 1c and Fig. S1 , available in JGV Online). These results indicated that the abolishment of NS1' formation in SA14-14-2-infected cells is possibly due to the G66A silent mutation that prevented the pseudoknot structure-dependent frameshift event.
To clarify the significance of the single nucleotide mutation G66A in NS2A on NS1' formation and attenuation, G66A was introduced into the infectious cDNA clone of JEV strain SA14 by standard site-directed mutagenesis. All the primers used in this study are listed in Table S1 . Equal amounts of RNA transcripts (1 mg) were obtained by in vitro transcription of linearized cDNA with SP6 RNA polymerase, and then transfected into BHK-21 cells with Lipofectamine 2000 (Invitrogen) as described previously (Li et al., 2010) . The recovered viruses were harvested after onset of typical cytopathic effect and named rSA14 and G66A, respectively. Immunofluorescence assays were performed at 24, 48 and 72 h post-transfection by using mice mAb 2A10G6 (Deng et al., 2011) . The results showed that transfection with RNA transcripts of rSA14 and G66A generated equivalent numbers of viral E protein-expressing cells (Fig. 2a) , indicating similar replication efficiency between the rSA14 and G66A RNAs. The rescued G66A virus yielded similar plaque morphology to the rSA14 virus in BHK-21 cells (Fig. 2b) . Then, one-step growth curves of rSA14 and G66A in BHK21 and human neuroblastoma SH-SY5Y cells were observed, respectively, and both viruses peaked at 48 h p.i., and no significant difference was observed between rSA14 and G66A (Fig. 2c) . Continuous passaging of G66A on BHK-21 cells for five rounds (4 days per round) did not change its plaque morphology, and sequencing of the mutant viruses showed that the engineered mutations were retained (data not shown). Next, to assess the impact of the G66A mutation on NS1' production, BHK-21, SH-SY5Y and C6/36 cells were separately infected with rSA14 and G66A at an m.o.i. of 0.1, and cell lysates harvested at 48 h p.i. were then subjected to Western blotting assay using 4M7 as described above. As shown in Fig. 2(d) , although NS1 and NS1' were observed in rSA14-infected BHK-21 cells, only NS1 was detected in the G66A-infected cells. The same expression pattern of NS1 and NS1' was also observed in SH-SY5Y and C6/36 cells (Fig. 2d) . These results strongly demonstrated that the single silent G66A mutation in NS2A abolished the production of NS1' in JEV-infected cells without affecting the replication properties.
Finally, to confirm the correlation of G66A mutation and viral virulence phenotype, groups of 3-week-old female BALB/c mice were inoculated intracranially and intraperitoneally with different doses of rSA14 and G66A. The same dose of SA14-14-2 was inoculated as a control. All the mice were monitored for signs of encephalitis or death for 15 days after inoculation. In the neurovirulence test, intracranial challenge of 2 and 20 p.f.u. of rSA14 caused 83.3 and 100 % mortality in mice, respectively, while 16.73 and 80 %, respectively, of mice inoculated with the corresponding dose of G66A died with typical encephalitis symptoms (Fig. 3a) . The mean survival time of G66A-infected mice was significantly longer than that of rSA14-inoculated mice (8.0 versus 10.0, P50.0138). In the neuroinvasiveness test, intraperitoneal challenge with 5610 6 p.f.u. of rSA14 killed all the mice within 10 days, while all the mice challenged with G66A survived without developing any encephalitis symptoms (Fig. 3b) . No mice died when inoculated with 1610 6 p.f.u. of either rSA14 or G66A. To compare the replication kinetic of the two viruses in mice, the brain tissues of the infected mice were collected at varying times p.i. and titrated by standard plaque-forming assay. The results showed that rSA14 could be detected in mice brain at day 3 p.i., and peaked at day 5 p.i., while G66A could not be detected at the indicated times in the neruovirulence test (Fig. 3c) . For the neuroinvasiveness test, rSA14 invaded mice brains at day 3 p.i., and peaked at day 5 p.i.; however, G66A could only be detected until day 5 p.i., and viral titre was significantly lower than that of rSA14 at the indicated times (Fig. 3d) . All the mice inoculated with varying doses of SA14-14-2 failed to kill any infected mice (Fig. 3) . Sequencing of viral progeny isolated from the brain of infected mice with signs of illness showed the retention of the introduced silent mutation (data not shown). Taken together, these results demonstrate that the single nt G66A mutation in the NS2A gene significantly disturbs viral replication in mice brain, thus decreasing neurovirulence and neuroinvasiveness in mice.
Previously, bioinformatic analysis suggested that NS1' of JEV serogroup flavivirus was a product of a 21 ribosomal frame shift event using a slippery heptanucleotide as a frameshift stimulating motif (Firth & Atkins, 2009) . Melian et al. (2010) demonstrated that the A30P mutation in NS2A disrupted the pseudoknot and abolished the production of NS1' of WNV. Our results showed that the additional nucleotide acid (G66) is critical for stabilizing the pseudoknot structure in the JEV-live vaccine strain (Fig. 1b and c) . This kind of frameshifting has been observed for many viruses (Brierley & The importance of NS1' production is not fully understood. During our submission, a manuscript in press also reported the deficiency in NS1' production in JEV SA14-14-2-infected cells, and the possible involvement of caspase was suggested (Sun et al., 2012) . Our results from reverse genetics showed that the single nucleotide mutation G66A abolished the production of NS1' in varying cells, both viruses showed the same growth properties and plaque morphology in mammalian and mosquito cells (Fig. 2) . Animal experiments clearly demonstrated the correlation of NS1' formation and enhanced virulence phenotype of JEV (Fig. 3) , which is in agreement with the recent finding from WNV (Melian et al., 2010) . Thus, we speculate that formation of NS1' should be recognized as a potential virulence marker for JEV serogroup flaviviruses. The silent mutation G66A is the first virulence determinant in NS2A of JEV to our knowledge.
However, G66A is still more virulent than the vaccine strain SA14-14-2 (Fig. 3) , indicating the existence of other virulence determinants. Full genome sequence analysis of SA14-14-2 revealed that dozens of amino acid mutations appeared during the attenuation history, and seven of them in the envelope protein have been suggested as critical amino acids for vaccine attenuation (Ni et al., 1994 (Ni et al., , 1995 Nitayaphan et al., 1990) . Previous studies based on reverse genetics have indicated the importance of the E138 mutation in the E protein (Arroyo et al., 2001; Zhao et al., 2005) . Recently, mutations in the 59 UTR were also suggested to be critical for the attenuation of SA14-14-2 (Chambers et al., 2007) . The contribution of other mutations throughout the genome to the attenuation of SA14-14-2 remains unclear.
In conclusion, we successfully demonstrated that the abolishment of NS1' formation of SA14-14-2 was due to the single nucleotide mutation (G66A) within the NS2A gene that prevented the pseudoknot structure-dependent frameshift event. Using reverse genetic technology and animal studies, we provide compelling evidence that the deficiency in NS1' formation was attributed to the attenuated phenotype of the JEV vaccine SA14-14-2. This finding is of critical importance for JE vaccine quality control. Currently, the WHO recommended live JE vaccine constituted more than 50 % of the global production of all JE vaccines (World Health Organization, 2005) . Considering the highly genetic stability of SA14-14-2 (Yu, 2010) , the unique 'A' nt at position 66 of the NS2A-coding sequence should be recognized as a critical attenuation marker for vaccine verification. and SA14-14-2, respectively. The mortality was monitored for 15 days after inoculation. The significance of differences in mortality between the rSA14-and G66A-inoculated groups was determined by using the log-rank test using GraphPad Prism 5.0. Mouse brain tissues from the neurovirulence (c) and neuroincasiveness (d) tests were separately harvested, homogenized and titrated by plaqueforming assay in BHK-21 cells. The dotted lines represent the limit of detection of the plaque assay for each mouse brain.
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